Form 4: Singular Genomics Systems Chief Scientific Officer Acquires Shares Through RSU Vesting
SEC Form 4 Filing
Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, acquired 250 shares of common stock through the vesting of restricted stock units.
Summary
- Eli N. Glezer, the Chief Scientific Officer of Singular Genomics Systems, acquired 250 shares of common stock on December 15, 2024.
- These shares were obtained through the vesting of restricted stock units (RSUs).
- Each RSU represents the right to receive one share of the company's common stock.
- Following this transaction, Mr. Glezer directly owns 155,083 shares of common stock.
- The RSUs vest in 16 equal quarterly installments over four years, starting from March 15, 2023.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to slightly positive. The acquisition of shares by a key executive can be seen as a positive sign of confidence.
Positives
- The vesting of RSUs is a standard part of executive compensation and aligns the executive's interests with those of the shareholders.
- The acquisition of shares by a key executive can be seen as a positive sign of confidence in the company's future.
Industry Context
This is a routine filing related to executive compensation and is common in publicly traded companies. It reflects the standard practice of using equity-based compensation to incentivize key personnel.
Comparison to Industry Standards
- The vesting schedule of RSUs over four years with quarterly installments is a common practice in the technology and biotech industries.
- Many companies, such as Illumina and Pacific Biosciences, use similar equity compensation structures for their executives.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 2023-03-15 | Start date for the vesting of the RSUs in 16 equal quarterly installments over four years. |
| 2024-12-15 | Date of the transaction where 250 shares were acquired through RSU vesting. |
| 2024-12-17 | Date the form was signed by Dalen Meeter, Attorney-in-Fact. |
Keywords
Singular Genomics Systems, stock acquisition, restricted stock units, RSU, executive compensation, insider trading, share ownership, Eli N. Glezer, OMIC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.